Parallel studies using STING-KO mice confirmed the strict requirement for STING expression in host but not tumor cells for therapeutic response to intratumoral administration of ADU-S100, including TLS formation and slowed tumor growth (67). The gene discussed is STING1; the disease is neoplasm.